Table 3.
Types of first-line treatments and the number of deaths during the 1st line treatment.
| Name of Schema | Number (%) of Cases during First Line | Number (%) of Deaths during First Line/with Drug Modification | |
|---|---|---|---|
| Treatment with Schema without Drug Modification | Treatment with Schema with Drug Modification | ||
| 3-Drug Schema | 157 (79.7%) | 12 (7.6%)/4 | |
| CTD (cyclophosphamide, thalidomide, dexamethasone) |
42 (21.3%) | 12 (6.1%) | 3 (5.6%)/2 |
| VMP (bortezomib, melphalan, prednisolone) |
38 (19.3%) | 1 (0.5%) | 6 (15.4%)/0 |
| MPT (melphalan, prednisolone, thalidomide) |
25 (12.7%) | 6 (3.0%) | 0/0 |
| VTD (bortezomib, thalidomide, dexamethasone) |
9 (4.6%) | 13 (6.6%) | 3 (13.7%)/2 |
| VCD (bortezomib, cyclophosphamide, dexamethasone) VRD (bortezomib, lenalidomide, dexamethasone) |
7 (3.6%) 1 (0.5%) |
3 (1.5%) 0 |
0/0 0/0 |
| 2-Drug Schema | 40 (20.3%) | 2 (5.0%)/1 | |
| VD (bortezomib, dexamethasone) | 5 (2.5%) | 6 (3.0%) | 0/0 |
| TD (thalidomide, dexamethasone) | 6 (3.0%) | 3 (1.5%) | 0/0 |
| MP (melphalan, prednisolone) | 4 (2.0%) | 6 (3.0%) | 1 (1.0%)/1 |
| CD (cyclophosphamide, dexamethasone) |
5 (2.5%) | 4 (2.0%) | 1 (1.1%)/0 |
| RD (lenalidomide, dexamethasone) |
1 (0.5%) | 0 | 0/0 |